Skip to main content

Health condition · Clinically reviewed

Kidney cancer, from an incidental scan to a curative plan.

Most kidney tumours are now found early and small. Nephron-sparing surgery, targeted therapy and immune checkpoint combinations have changed what is possible.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, EAU and NCCN standards you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice: nephron-sparing surgery, immune checkpoint combinations and belzutifan for VHL-associated disease.

Key facts

Kidney cancer at a glance.

The essentials in plain English - what it is, the histological subtypes, and how it is treated in the UK today.

  • What it is

    A malignant tumour arising from the renal parenchyma or upper tract urothelium. Around 13,500 new UK cases each year.

  • Types

    Clear cell (about 75%), papillary type 1 and 2 (about 15%), chromophobe (about 5%), collecting duct and medullary, upper-tract urothelial, Wilms tumour in children, and sarcomatoid variants.

  • Presentation

    Most tumours are found incidentally on imaging. The classic triad of haematuria, flank pain and a palpable mass is now rare and late.

  • First-line imaging

    Ultrasound and a triple-phase CT of the abdomen and chest are the mainstay. MRI is selective, biopsy specialist commissioned.

  • Localised disease

    Partial nephrectomy is preferred where feasible. Thermal ablation is an option for small renal masses in selected patients.

  • Metastatic disease

    Immune checkpoint combinations and targeted TKIs have transformed outcomes. Belzutifan is emerging for VHL-associated tumours.

Why this guide matters

Early imaging, kidney-sparing surgery, and modern systemic therapy.

The three points below shape everything else on this page - from a symptomless CT finding to a full metastatic treatment plan.

  • Most tumours are found early

    Over half of renal masses are picked up incidentally on scans done for something else - and small tumours are highly curable.

  • Nephron-sparing surgery wins

    Partial nephrectomy preserves renal function without compromising cancer outcomes in most T1 tumours.

  • Immunotherapy has changed prognosis

    Immune checkpoint combinations and targeted TKIs deliver durable responses that were unimaginable a decade ago.

How the diagnosis is made

From first scan to a definitive plan.

The steps a UK urologist and MDT will normally follow, in order - so you know what to expect and why each test matters.

  1. 01

    Assessing

    History and red flags

    Smoking, obesity, hypertension, occupational exposures, dialysis, family history and any suggestion of a hereditary syndrome.

  2. 02

    Assessing

    Examination and urine

    Abdominal, flank and lymph-node examination alongside urinalysis for microscopic and visible haematuria.

  3. 03

    Assessing

    Baseline bloods

    FBC, LFTs, U&Es, calcium and LDH. Polycythaemia and hypercalcaemia can be paraneoplastic clues.

  4. 04

    Confirming

    Renal ultrasound

    Usually the first-line imaging test - simple, fast and helpful to characterise cystic lesions.

  5. 05

    Confirming

    Triple-phase CT abdomen and chest

    The gold-standard staging test. Bosniak classification stratifies cystic lesions and CT of the chest looks for pulmonary metastases.

  6. 06

    Confirming

    MRI and biopsy - selective

    MRI when CT contrast is contraindicated or vascular involvement is suspected. Percutaneous biopsy in selected small renal masses.

  7. 07

    Preparing

    MDT and molecular profiling

    Specialist-commissioned urology cancer centres. Germline testing where a hereditary syndrome is suspected and tumour molecular profiling to guide systemic therapy.

Typical timeline: from first scan to MDT decision in a matter of weeks.

Symptoms

What kidney cancer actually looks like.

Often silent, sometimes systemic, occasionally dramatic. And the features that mean urgent imaging is warranted.

  • Incidental finding

    More than half of renal tumours are found on scans done for something else - often small, contained and highly curable.

  • Visible or microscopic haematuria

    Blood in the urine is the single most common presenting symptom - and always deserves a two-week wait referral.

  • Flank pain

    Dull, persistent loin ache from local stretch or clot colic. Sharp pain suggests bleeding into the tumour.

  • Palpable mass

    A firm loin mass is a late sign now - most tumours are diagnosed long before this stage.

  • Systemic symptoms

    Fatigue, weight loss, night sweats and low-grade fever - the constitutional signature of a paraneoplastic tumour.

  • Paraneoplastic syndromes

    Polycythaemia from ectopic erythropoietin, hypercalcaemia from PTHrP and hypertension from renin excess.

  • Varicocele

    A new left-sided varicocele that does not empty on lying down can signal renal-vein tumour thrombus.

  • Red flag - features of metastasis

    Bone pain, breathlessness, jaundice or new neurology - metastases to lung, bone, liver and brain need urgent staging.

Treatment

How kidney cancer is treated in the UK.

Surgery first for localised disease, active surveillance and ablation for selected small tumours, and immune checkpoint combinations with targeted therapy for advanced disease.

  • Partial nephrectomy

    Nephron-sparing surgery is the preferred option for T1 tumours - open, laparoscopic or robotic - specialist commissioned.

  • Radical nephrectomy

    For larger or centrally placed tumours where partial resection is not feasible - laparoscopic or robotic where possible.

  • Thermal ablation

    Radiofrequency, cryoablation or microwave ablation for small renal masses in patients unfit for surgery or with hereditary tumours.

  • Active surveillance

    A structured watch-and-scan strategy for small renal masses under 4cm - safe, evidence-based and specialist-led.

  • Adjuvant pembrolizumab

    Approved in 2022 for high-risk resected clear-cell disease - reduces recurrence in carefully selected patients.

  • Immune checkpoint combinations

    Nivolumab plus ipilimumab, pembrolizumab plus axitinib or lenvatinib, and nivolumab plus cabozantinib for first-line metastatic disease.

  • TKIs and mTOR inhibitors

    Sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib and tivozanib; everolimus and temsirolimus in later lines.

  • Belzutifan and supportive care

    HIF-2α inhibition for VHL-associated tumours. Stereotactic radiosurgery, bone-modifying agents and palliative input where needed.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and international specialist standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your urologist or oncologist knows your imaging, histology and comorbidities and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Renal cancer: management (NG233) and referral guidance (NG12).

  • European Association of Urology (EAU). Guidelines on renal cell carcinoma.

  • NCCN. Clinical Practice Guidelines in Oncology - Kidney Cancer.

  • MHRA and NHS England. Commissioning statements for immune checkpoint therapy and belzutifan.

Red flags

When kidney cancer needs urgent attention.

Most patients are managed through a specialist urology cancer MDT. These are the features that push a case to the top of the list.

  • Visible haematuria

    Any visible blood in urine in an adult is a two-week wait referral until proven otherwise. Do not wait for it to settle.

  • Loin mass with weight loss

    The classic late presentation - a palpable mass alongside constitutional symptoms needs urgent imaging and staging.

  • New left varicocele

    A left-sided varicocele that does not empty on lying flat can indicate renal-vein tumour thrombus - image urgently.

  • Symptomatic hypercalcaemia

    Confusion, constipation and polyuria in a patient with a known or suspected renal mass - see /conditions/hypercalcemia/ and treat promptly.

  • Bone pain or pathological fracture

    Skeletal metastases can be the first sign. Urgent orthopaedic and oncology review, radiotherapy and bone-modifying agents.

  • Neurological signs

    New headache, seizure or focal deficit in a renal cancer patient - suspect brain metastases and image without delay.

  • Hereditary syndrome features

    Retinal angiomas, cerebellar haemangioblastomas, phaeochromocytoma or a strong family history - see /conditions/von-hippel-lindau-syndrome/.

  • Unexplained polycythaemia

    A raised haematocrit without another cause can be a paraneoplastic marker - image the kidneys before labelling it primary.

  • Rapid tumour growth on surveillance

    A small renal mass growing faster than expected needs early MDT review and definitive treatment.

Living with it

A treatable cancer, with a clear pathway.

Four things that make the biggest difference after diagnosis - keeping to a surveillance plan, protecting the remaining kidney, considering genetics and drawing on peer support.

A quiet reminder

Consistency in follow-up matters as much as the operation itself.

Structured imaging picks up recurrence early - when it is still curable. Keep every appointment, even the ones that feel unnecessary.

  1. 01 Routine

    Structured follow-up

    Post-treatment surveillance follows a schedule of imaging and blood tests - keep the appointments even when you feel well.

  2. 02 Kidney

    Protect the remaining kidney

    Blood pressure control, sensible fluid intake and avoiding nephrotoxic drugs matters more once a kidney has been removed.

  3. 03 Family

    Consider genetic testing

    Young onset, bilateral tumours or a striking family history should prompt a specialist genetics conversation for you and your relatives.

  4. 04 Support

    Kidney Cancer UK

    Peer support, financial advice and up-to-date information from a specialist charity make a real difference to living well after diagnosis.

Frequently asked

Everything we get asked about kidney cancer.

Quick answers on subtypes, imaging, nephron-sparing surgery, immune checkpoint therapy and hereditary risk.

  • What is kidney cancer?

    A malignant tumour of the kidney. The commonest type is renal cell carcinoma - a cancer of the tubular cells of the renal parenchyma. Around 13,500 new cases are diagnosed in the UK each year, and most are now found incidentally on imaging done for another reason.

  • What symptoms should prompt a referral?

    Visible haematuria in an adult is a two-week wait referral in its own right. Unexplained loin pain or mass, weight loss with fatigue, a new left varicocele, polycythaemia or hypercalcaemia without another cause also deserve urgent imaging and specialist review.

  • How is kidney cancer diagnosed?

    Renal ultrasound is usually first, followed by a triple-phase CT scan of the abdomen and chest to characterise the mass and stage the disease. MRI is used when CT contrast is contraindicated or vascular invasion is suspected. Percutaneous biopsy is reserved for small renal masses where the result would change management.

  • Can a kidney tumour be treated without removing the whole kidney?

    Yes - partial nephrectomy is preferred for most T1 tumours. Nephron-sparing surgery preserves renal function without compromising cancer outcomes. In selected small renal masses, thermal ablation or active surveillance are appropriate alternatives to open surgery.

  • What treatments are used for metastatic kidney cancer?

    First-line therapy is now an immune checkpoint combination - typically nivolumab plus ipilimumab, or a checkpoint inhibitor with a targeted TKI such as axitinib, lenvatinib or cabozantinib. Later lines use TKI monotherapy and mTOR inhibitors. Belzutifan is emerging for VHL-associated tumours.

  • Is kidney cancer hereditary?

    The vast majority of cases are sporadic, but hereditary syndromes account for a small proportion. Von Hippel-Lindau syndrome, Birt-Hogg-Dubé, hereditary leiomyomatosis and renal cell cancer (HLRCC) and tuberous sclerosis all raise the risk. Bilateral, multifocal or young-onset disease should trigger a genetics referral.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.